Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training in Heart Failure With Preserved Ejection Fraction (HFpEF) (INABLE-Training)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-09-30

Study Completion Date

2022-04-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Participants with heart failure with preserved ejection fraction will undergo 12 weeks of cardiac rehabilitation for exercise training (ET) and be randomized to either sodium nitrite or placebo through the training period. Study drug is administered 3 times daily with one of these doses being 30 minutes prior to onset of ET sessions throughout the12 week trial. The objective is to determine if the sodium nitrite improves the clinical responses and tolerability of ET.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF

NCT02742129

Heart Failure

COMPLETED PHASE2

Inorganic NItrate and EXercise Performance in Heart Failure (iNIX-HF): Dose Response

NCT02797184

Heart Failure

COMPLETED PHASE1/PHASE2

Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction

NCT01932606

Heart Disease Heart Failure With Preserved Ejection Fraction Exercise Intolerance +1 more

COMPLETED PHASE2

Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction

NCT02262078

Heart Failure

COMPLETED PHASE2

The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)

NCT05562167

Heart Failure

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Subjects will undergo cardiac exercise training and receive inhaled or oral placebo three times per day for 12 weeks while wearing an accelerometer

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

administered orally or inhaled, taken every 4 hours or 3 times per day during waking hours for 12 weeks

Accelerometer

Intervention Type DEVICE

External triaxial accelerometer is worn externally at the hip during exercise training sessions, and day/night to continuously measure activity levels, removed for bathing only.

Cardiac Exercise Training

Intervention Type OTHER

Cardiac rehabilitation exercise training consisting of supervised endurance and strength exercise training of approximately one hour, 3 times per week for 12 weeks.

Sodium Nitrite

Subjects will undergo cardiac exercise training and receive inhaled or oral sodium nitrite three times per day for 12 weeks while wearing an accelerometer

Group Type ACTIVE_COMPARATOR

Sodium Nitrite

Intervention Type DRUG

administered orally or inhaled, 40 mg, taken every 4 hours or 3 times per day during waking hours for 12 weeks

Accelerometer

Intervention Type DEVICE

External triaxial accelerometer is worn externally at the hip during exercise training sessions, and day/night to continuously measure activity levels, removed for bathing only.

Cardiac Exercise Training

Intervention Type OTHER

Cardiac rehabilitation exercise training consisting of supervised endurance and strength exercise training of approximately one hour, 3 times per week for 12 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

administered orally or inhaled, taken every 4 hours or 3 times per day during waking hours for 12 weeks

Intervention Type DRUG

Sodium Nitrite

administered orally or inhaled, 40 mg, taken every 4 hours or 3 times per day during waking hours for 12 weeks

Intervention Type DRUG

Accelerometer

External triaxial accelerometer is worn externally at the hip during exercise training sessions, and day/night to continuously measure activity levels, removed for bathing only.

Intervention Type DEVICE

Cardiac Exercise Training

Cardiac rehabilitation exercise training consisting of supervised endurance and strength exercise training of approximately one hour, 3 times per week for 12 weeks.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nitrite

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 40 years
* Symptoms of dyspnea (II-IV) without evidence of a non-cardiac or ischemic explanation for dyspnea
* Ejection Fraction (EF) of \> or = 50% determined on most recent imaging study within the preceding 5 years, with no change in clinical status suggesting potential for deterioration in systolic function
* One of the following:

* Previous hospitalization for Heart Failure (HF) with radiographic evidence (pulmonary venous hypertension, vascular congestion, interstitial edema, pleural effusion) of pulmonary congestion or
* Catheterization documented elevated filling pressures at rest (Pulmonary Capillary Wedge Pressure (PCWP)= ≥15 or Left Ventricular End-Diastolic Pressure (LVEDP) ≥18) or with exercise (PCWP ≥25) or
* Elevated Natruretic Peptide-proBNP (\>400 pg/ml) or B-Type Natriuretic Peptide (BNP)(\>200 pg/ml) or
* Echo evidence of diastolic dysfunction/elevated filling pressures manifest by medial E/e' ratio≥15 and/or left atrial enlargement and chronic treatment with a diuretic for signs or symptoms of heart failure
* Heart failure is primary factor limiting activity as indicated by answering # 2 to the following question:

My ability to be active is most limited by:

1. Joint, foot, leg, hip or back pain
2. Shortness of breath and/or fatigue and/or chest pain
3. Unsteadiness or dizziness
4. Lifestyle, weather, or I just don't like to be active

* No chronic nitrate therapy or not using intermittent sublingual nitroglycerin (requirement for \>1 sublingual nitroglycerin per week).
* No daily use of phosphodiesterase 5 (PDE5) inhibitors or soluble guanylyl cyclase activators and willing to withhold as needed use of PDE5 inhibitors for duration of study
* Ambulatory (not wheelchair / scooter dependent)
* Body size allows wearing of the accelerometer belt as confirmed by ability to comfortably fasten the test belt provided for the screening process.
* Willingness to wear the accelerometer belt for the duration of the trial

Exclusion Criteria

* Recent (\< 1 month) hospitalization for heart failure
* Ongoing requirement for PDE5 inhibitor, organic nitrate or soluble guanylyl cyclase activators
* Hemoglobin (Hgb) \< 8.0 g/dl within 30 days prior to randomization
* Glomerular Filtration Rate (GFR) \< 20 ml/min/1.73 m2 within 30 days prior to randomization
* Systolic blood pressure \< 115 mmHg seated or \< 90 mmHg standing
* Resting Heart Rate \> 110
* Previous adverse reaction to the study drug which necessitated withdrawal of therapy
* Significant chronic obstructive pulmonary disease that is a primary contributor to symptoms, in the opinion of the Investigator.
* Ischemia thought to contribute to dyspnea, in the opinion of the Investigator.
* Documentation of previous Ejection Fraction \< 40%
* Acute coronary syndrome within 3 months defined by electrocardiographic (ECG) changes and biomarkers of myocardial necrosis (e.g., troponin) in an appropriate clinical setting (chest discomfort or anginal equivalent)
* Percutaneous Coronary Intervention, coronary artery bypass grafting, or new biventricular pacing within past 3 months
* Obstructive hypertrophic cardiomyopathy
* Known infiltrative cardiomyopathy (amyloid)
* Constrictive pericarditis or tamponade
* Active myocarditis
* Complex congenital heart disease
* Active collagen vascular disease
* More than mild aortic or mitral stenosis
* Intrinsic (prolapse, rheumatic) valve disease with more than moderate mitral, tricuspid or aortic regurgitation
* Acute or chronic severe liver disease as evidenced by any of the following: encephalopathy, variceal bleeding, International Normalized Ratio (INR) \> 1.7 in the absence of anticoagulation treatment
* Terminal illness (other than HF) with expected survival of less than 1 year
* Enrollment or planned enrollment in another therapeutic clinical trial in next 3 months.
* Inability to comply with planned study procedures
* Pregnancy or breastfeeding mothers

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No